Port developer Abu Dhabi Ports has announced that it will store and distribute more than 70 million Covid-19 vaccines as part of its efforts to support the global fight against the virus.
Hope Consortium, a UAE-based public-private partnership, of which Abu Dhabi Ports is a member, will also facilitate the worldwide distribution of the vaccines.
The company has dedicated a 19,000m² temperature-controlled warehouse centre in Khalifa Industrial Zone Abu Dhabi (KIZAD), which already houses more than one million vials of the vaccine.
This facility can stock vaccines and other pharmaceutical products at a temperature range of 2°C to 8°C and at -80°C.
It also has temperature and humidity systems examined digitally through a control dashboard.
The Hope Consortium represents the supply chain solution players in Abu Dhabi and led by the Department of Health of Abu Dhabi.
It also includes Etihad Cargo, Rafed, the healthcare procurement company created by ADQ, and SkyCell, a Swiss-based provider of temperature-controlled container solutions.
Abu Dhabi Ports group CEO Captain Mohamed Juma Al Shamisi said: “As our nation’s key strategic logistics enabler, we have invested in one of the region’s largest and most expansive logistics capabilities. This makes us uniquely positioned to support our government’s vision and facilitate the immunisation efforts to positively impact millions of lives. Abu Dhabi Ports is ready to play a leading role in the end-to-end supply chain including storing, processing, and distributing this extremely sensitive product.”
Abu Dhabi Department of Health undersecretary Jamal Mohammed Alkaabi said: “Abu Dhabi continues to play a vital role within the global effort to discover a vaccine for COVID-19. And as part of those efforts, we are providing logistical capabilities that will position the UAE as a distinguished local, regional, and global distribution hub.
“At the Department of Health, we have aligned our vaccine storage processes with the best international practices governing the long-term storage of pharmaceutical products, which will ensure the efficiency of vaccines. Such a robust solution was necessary because the vaccines are composed of genetic and protein ingredients and must be stored in optimal temperatures for the longest possible period to ensure their effectiveness when finally used.”